Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease
Authors:
- A. N. BogolepovaABA. N. Bogolepova
- E. E. VaseninaEVE. E. Vasenina
- N. V. VakhninaNVN. V. Vakhnina
- S. I. GavrilovaSGS. I. Gavrilova
- А. Yu. EmelinАEА. Yu. Emelin
- V. V. ZakharovVZV. V. Zakharov
- S. N. IllarioshkinSIS. N. Illarioshkin
- O. V. KosivtsovaOKO. V. Kosivtsova
- G. P. KostyukGKG. P. Kostyuk
- O. S. LevinOLO. S. Levin
- E. A. MkhitaryanEME. A. Mkhitaryan
Open Access
- 20 October 2024
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (5) , 111-119
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease and the most common cause of dementia. In daily practice, AD is often diagnosed late, while the early stages of the disease are overlooked or mistaken for cerebrovascular pathology. However, the efficacy of existing and newly developed (disease-modifying) AD therapies is the greatest in the early stages of the disease. An accurate diagnosis of AD is possible when biological markers of the main pathological process (cerebral amyloidosis, tauopathy) are detected using positron emission tomography or neurochemical examination of cerebrospinal fluid, which are gradually being introduced into practice in Russia. The experts discussed the clinical aspects of the use of biological markers, obtained in the leading specialized centers of our country for the diagnosis and treatment of cognitive impairment (CI). First and foremost, biomarker testing is indicated in patients with mild CI and mild dementia possibly associated with AD, so that disease-modifying (pathogenetic) therapy can be initiated as early as possible upon on its availability (currently, drugs for anti-amyloid disease-modifying therapy are not registered in the Russian Federation). Patients with a non-classical (non-amnestic) or atypical AD phenotype are another group of patients in whom it is also advisable to analyze biomarkers for differential diagnostic purposes.Keywords
This publication has 37 references indexed in Scilit:
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- The probabilistic model of Alzheimer disease: the amyloid hypothesis revisedNature Reviews Neuroscience, 2021
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s diseaseAgeing Research Reviews, 2021
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working GroupThe Lancet Neurology, 2021
- Current and Future Treatments in Alzheimer's DiseaseSeminars in Neurology, 2019
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohortNeuroImage: Clinical, 2018
- Consensus classification of posterior cortical atrophyAlzheimer's & Dementia, 2017
- Cognition and anatomy in three variants of primary progressive aphasiaAnnals of Neurology, 2004
- The Mini-Cog: a cognitive ?vital signs? measure for dementia screening in multi-lingual elderlyInternational Journal of Geriatric Psychiatry, 2000